Compare stocks

bioMérieux S.A. is a French company specialized in the field of in vitro diagnostics, operating within the healthcare industry. The company develops, manufactures, and markets diagnostic solutions that are primarily used for detecting disease-causing microorganisms. These solutions include a broad range of products, such as diagnostic tests for infectious diseases, cancer, and cardiovascular diseases, as well as industrial microbiological controls. Founded in 1963 by Alain Mérieux, bioMérieux is headquartered in Marcy-l'Étoile, near Lyon, France. The company has a global presence, serving clients around the world through a network of subsidiaries and distributors. Its competitive strength lies in its extensive product portfolio and commitment to research and development, enabling it to address evolving medical and industrial testing needs.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.